2019
DOI: 10.3332/ecancer.2019.937
|View full text |Cite
|
Sign up to set email alerts
|

Depression and quality of life in patients with breast cancer undergoing chemotherapy and monoclonal antibodies

Abstract: Background Depression is one of the major psychiatric morbidities in cancer patients. The purpose of our study was to evaluate the impact of depressive symptoms in the quality of life (QoL) of patients with breast cancer undergoing chemotherapy and monoclonal antibodies treatments. Methods Observational, cross-sectional study conducted between April and November 2016. To evaluate the QoL, the EORTC QLQ-C30 and QLQ-BR23 questionnaire were used. The patients were screened… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
16
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 15 publications
(19 citation statements)
references
References 36 publications
1
16
0
1
Order By: Relevance
“…Although few studies have examined the relationship between depression and HRQOL in patients with gastric cancer, the findings of previous studies on other types of cancer have supported the negative association between depression and HRQOL. For example, among patients with esophageal cancer [ 21 ], prostate cancer [ 31 ], gynecological cancer [ 24 ], hematological cancer [ 32 ], and breast cancer undergoing chemotherapy [ 33 ], depression was identified as an independent risk factor for reducing various aspects of HRQOL. Depression is characterized by feelings of sadness and can result in severe impairments that interfere with or limit one’s ability to carry out major life activities, both at work and at home [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…Although few studies have examined the relationship between depression and HRQOL in patients with gastric cancer, the findings of previous studies on other types of cancer have supported the negative association between depression and HRQOL. For example, among patients with esophageal cancer [ 21 ], prostate cancer [ 31 ], gynecological cancer [ 24 ], hematological cancer [ 32 ], and breast cancer undergoing chemotherapy [ 33 ], depression was identified as an independent risk factor for reducing various aspects of HRQOL. Depression is characterized by feelings of sadness and can result in severe impairments that interfere with or limit one’s ability to carry out major life activities, both at work and at home [ 34 ].…”
Section: Discussionmentioning
confidence: 99%
“…Faktor lain yang dapat mempengaruhi kualitas hidup pasien QLQ-C30 adalah penggunaan antibodi monoklonal, pasien yang menjalani kemoterapi dengan antibodi monoklonal memiliki kualitas hidup yang baik, perbedaan yang signifikan terdapat pada fungsi peran. Sedangkan gejala yang tidak diinginkan juga terjadi pada kelompok kemoterapi yang tidak mendapatkan antibodi monoklonal (Trinca et al, 2019).…”
Section: Kualitas Hidupunclassified
“…As cancer becomes a chronic condition rather than a life-threatening illness, the health care community must learn to recognize and manage the long-term sequelae of physical and psychological side effects of treatment protocols. Major issues receiving the most attention include chronic inflammation [3,4], increased risk of second primary malignancies [5], pain and muscle weakness [6], depression and anxiety [7][8][9][10], fatigue [11], sleep disturbance [12], dryness of the mouth [13,14], and less threatening medical conditions. In addition, preexisting comorbidities such as obesity, hypertension, hyperlipidemia, and diabetes will most certainly affect disease-free survival, and ultimately, overall survival [15].…”
Section: Introductionmentioning
confidence: 99%